UNS 0.00% 0.5¢ unilife corporation

loss of director

  1. 591 Posts.



    Compare Brokers
    AdChoices





    • Former UNIS Sr Dir responsible for ID, qualif, and negot of commercial develop - moves on to MonoSol Rx as Director, Business Development
      Just linked from Google Finance news - MonoSol Rx Appoints Joseph Crusco Director of Business Development July 10, 2014, 8:30 a.m. EDT

      WARREN, N.J., Jul 10, 2014 (GLOBE NEWSWIRE via COMTEX) --
      MonoSol Rx, the developer of PharmFilm® drug delivery technology, today announced the appointment of Joseph Crusco to the position of Director, Business Development. Mr. Crusco will report to Dan Barber, Vice President of Business Development, and will be responsible for leading MonoSol Rx's business development activities including implementing the company's' licensing and strategic partnering strategy.
      A. Mark Schobel, Chief Executive Officer of MonoSol Rx said, "We are pleased to welcome Joe to the MonoSol Rx team. He is an important strategic addition as we intensify our business development efforts to meet our near- and longer-term growth objectives. Joe is a highly accomplished, forward-thinking professional with a great deal of sales, business and commercial expertise. His strong product knowledge, background and relationships in the pharmaceutical, biotech and vaccine industries will be invaluable as we expand our business moving forward."
      Prior to joining MonoSol Rx, Crusco was Senior Director at Unilife Corporation where he was responsible for identification, qualification and negotiation of commercial development opportunities for Unilife's injection system product Platform. Previously, Joe was the Marketing and Business Development Director at Datwyler Pharma Packaging, where he was responsible for developing strategies for Datwyler's strategic target markets (vaccines, diabetic care, and biotech). From 2002 through 2011, Joe was a Strategic Key Account Manager for Becton Dickinson Pharmaceutical Systems where he held responsibility for all sales and commercial development activities for large commercial pharmaceutical and biotech accounts totaling approximately $41 million in annual revenue.
      Joe holds a BS in Human Ecology
 
watchlist Created with Sketch. Add UNS (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.